Azenta, Inc. (AZTA) – What Are Investment Firms Thinking About This Stock?

Shares of Azenta, Inc. (NASDAQ:AZTA) have received a consensus rating of “Hold” from the seven analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $43.60.

Several research analysts have recently weighed in on AZTA shares. Weiss Ratings upgraded shares of Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 26th. Needham & Company LLC reiterated a “buy” rating and issued a $37.00 target price on shares of Azenta in a research note on Monday, September 14th. Wall Street Zen cut Azenta from a “buy” rating to a “hold” rating in a report on Sunday, October 18th. Finally, Jefferies Financial Group boosted their price target on Azenta from $44.00 to $52.00 and gave the stock a “buy” rating in a research report on Wednesday.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in shares of Azenta during the 2nd quarter worth about $192,152,000. GW&K Investment Management LLC grew its stake in Azenta by 0.4% in the 3rd quarter. GW&K Investment Management LLC now owns 992,616 shares of the company’s stock valued at $34,633,000 after buying an additional 4,187 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in Azenta by 16.3% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 1,613,914 shares of the company’s stock valued at $34,183,000 after buying an additional 225,867 shares during the last quarter. Front Street Capital Management Inc. bought a new position in Azenta in the 2nd quarter valued at about $33,212,000. Finally, American Capital Management Inc. raised its holdings in Azenta by 26.9% in the 1st quarter. American Capital Management Inc. now owns 1,296,024 shares of the company’s stock valued at $27,385,000 after acquiring an additional 274,588 shares during the period. 99.08% of the stock is owned by institutional investors and hedge funds.

Azenta Trading Up 20.8%

NASDAQ:AZTA opened at $48.90 on Friday. The stock has a market capitalization of $2.14 billion, a PE ratio of -13.51 and a beta of 1.47. Azenta has a 1-year low of $15.93 and a 1-year high of $50.06. The firm has a fifty day simple moving average of $35.98 and a 200 day simple moving average of $28.51.

Azenta (NASDAQ:AZTA) last posted its quarterly earnings results on Tuesday, November 10th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.17. The firm had revenue of $167.09 million for the quarter, compared to analyst estimates of $160.16 million. Azenta had a negative net margin of 26.86% and a positive return on equity of 1.37%.

Latest Azenta News

Investors following AZTA have been watching these news items:

• Positive Sentiment: Jefferies raised its price target from $44 to $52 and maintained a Buy rating, signaling improved analyst expectations following the results. Jefferies recommendations
• Positive Sentiment: The company repurchased 4.4 million shares for $118.2 million in FY2026 and ended September with about $506 million in cash and marketable securities, providing financial flexibility and a potential per-share tailwind. InvestorPlace coverage of Azenta buybacks and outlook
• Negative Sentiment: Rosen Law Firm said it is investigating potential securities claims related to allegations that Azenta may have provided materially misleading business information. The claims are allegations, not established findings, but the investigation adds legal uncertainty. Rosen Law Firm investigation announcement

Azenta Company Profile

Azenta, Inc. provides products and services for life sciences research and the management of biological samples. Its offerings include automated sample storage systems, laboratory automation equipment, consumables, and software used to track and manage samples. The company also provides genomic services through GENEWIZ, including sequencing and other genetic analysis services for researchers and organizations in the life sciences and pharmaceutical industries. Azenta was formed in 2021 when Brooks Automation separated its life sciences business and adopted the Azenta name.